By tracking plasmids that were selectively depleted, we identified over 100 candidate phage trigger- E. coli pairs. Two phage trigger proteins were investigated in detail, revealing a novel antiphage ...

Several techniques allow monoclonal antibody development, the most common being hybridoma, phage display, and B-cell cloning.

The primary criticism of phage therapy is generally that a paucity of modern, double-blinded, Phase III (efficacy) clinical trials in humans have been undertaken and, therefore, a substantial ...

As difficult-to-treat infections continue to rise, phage therapies are becoming important complements to existing treatments.

As antibiotic resistance reaches critical levels worldwide, the 8th World Congress on Targeting Phage Therapy (June 10–11, 2025) returns to Berlin, bringing together over 75 international ...

These methods are typically categorised into: 1. in vivo methods, such as hybridoma technology and single B-cell technologies (collectively called in vivo technologies) 2. in vitro methods, such as ...

In turn, a phage will try to coevolve with the bacteria to maintain its infectivity. Sometimes a phage can change to better infect its target bacteria, but sometimes the bacteria can outsmart it.

Phage display often uses a type of phage known as filamentous, so called because they are long and thin, making the display of many proteins across its surface possible.

Hybridoma Technology for Monoclonal Antibody Production By fusing antibody-producing cells with immortal myeloma cells, researchers create hybridomas that produce reliable supplies of highly specific ...